EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266–283 antitumor response in preclinical glioblastoma models
Neuro-Oncology · 05.07.2024 · 26 (7) · 1230-1246
DOI: 10.1093/neuonc/noae060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 20.03.2024. Verfasst von Andrea Álvarez-Vázquez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Neuroscience Institute of Castilla y León (INCyL), Institute for Biomedical Research of Salamanca (…. Hauptthemen laut MEDLINE: Glioblastoma, ErbB Receptors, Brain Neoplasms, Gene Amplification. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Junta de Castilla y León, IBSAL, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background
Glioblastoma (GBM) commonly displays epidermal growth factor receptor (EGFR) alterations (mainly amplification and EGFRvIII) and TAT-Cx43266–283 is a Src-inhibitory peptide with antitumor properties in preclinical GBM models. Given the link between EGFR and Src, the aim of this study was to explore the role of EGFR in the antitumor effects of TAT-Cx43266–283.
Methods
The effect of TAT-Cx43266–283, temozolomide (TMZ), and erlotinib (EGFR inhibitor) was studied in patient-derived GBM stem cells (GSCs) and murine neural stem cells (NSCs) with and without EGFR alterations, in vitro and in vivo. EGFR alterations were analyzed by western blot and fluorescence in situ hybridization in these cells, and compared with Src activity and survival in GBM samples from The Cancer Genome Atlas.
Results
The effect of TAT-Cx43266–283 correlated with EGFR alterations in a set of patient-derived GSCs and was stronger than that exerted by TMZ and erlotinib. In fact, TAT-Cx43266-283 only affected NSCs with EGFR alterations, but not healthy NSCs. EGFR alterations correlated with Src activity and poor survival in GBM patients. Finally, tumors generated from NSCs with EGFR alterations showed a decrease in growth, invasiveness, and vascularization after treatment with TAT-Cx43266–283, which enhanced the survival of immunocompetent mice.
Conclusions
Clinically relevant EGFR alterations are predictors of TAT-Cx43266–283 response and part of its mechanism of action, even in TMZ- and erlotinib-resistant GSCs. TAT-Cx43266–283 targets NSCs with GBM-driver mutations, including EGFR alterations, in an immunocompetent GBM model in vivo, suggesting a promising effect on GBM recurrence. Together, this study represents an important step toward the clinical application of TAT-Cx43266–283.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Neuroscience Institute of Castilla y León (INCyL), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain.
- Centre for Cancer Research-IBMCC (CSIC), IBSAL, Salamanca, Spain.
- Instituto de investigaciones Biomédicas I+12 (Imas12), Hospital 12 de Octubre, Madrid, Spain.
- Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.
- Centre for Regenerative Medicine, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.
- Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID-Profile: Andrea Álvarez-Vázquez, Laura San-Segundo, Raquel Flores-Hernández, Claudia Ollauri-Ibáñez, Berta Segura-Collar, Christopher G Hubert, Steven M Pollard, Justin D Lathia, Pilar Sánchez-Gómez, Arantxa Tabernero
Förderung
- Junta de Castilla y León
- IBSAL
- Instituto de Salud Carlos III
- Cleveland Clinic Lerner Research Institute and Case Comprehensive Center
- Ministerio de Ciencia e Innovación
Zitieren
APA
Álvarez-Vázquez, A., San-Segundo, L., Cerveró-García, P., Flores-Hernández, R., Ollauri-Ibáñez, C., Segura-Collar, B., Hubert, C. G., Morrison, G., Pollard, S. M., Lathia, J. D., Sánchez-Gómez, P., & Tabernero, A. (2024). EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266–283 antitumor response in preclinical glioblastoma models. Neuro-Oncology, 26(7), 1230-1246. https://doi.org/10.1093/neuonc/noae060
Vancouver
Álvarez-Vázquez A, San-Segundo L, Cerveró-García P, Flores-Hernández R, Ollauri-Ibáñez C, Segura-Collar B, et al. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266–283 antitumor response in preclinical glioblastoma models. Neuro-Oncology. 2024;26(7):1230-1246. doi:10.1093/neuonc/noae060
BibTeX
@article{lvarezVzquez2024,
author = {Álvarez-Vázquez, Andrea and San-Segundo, Laura and Cerveró-García, Pilar and Flores-Hernández, Raquel and Ollauri-Ibáñez, Claudia and Segura-Collar, Berta and Hubert, Christopher G and Morrison, Gillian and Pollard, Steven M and Lathia, Justin D and Sánchez-Gómez, Pilar and Tabernero, Arantxa},
title = {EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266–283 antitumor response in preclinical glioblastoma models},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {7},
pages = {1230--1246},
doi = {10.1093/neuonc/noae060}
}
EUVIMED